These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC Nat Immunol; 2019 Feb; 20(2):206-217. PubMed ID: 30664764 [TBL] [Abstract][Full Text] [Related]
23. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. Bellone M; Elia AR Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732 [TBL] [Abstract][Full Text] [Related]
24. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
25. The use of immunotherapy in the treatment of melanoma. Achkar T; Tarhini AA J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398 [TBL] [Abstract][Full Text] [Related]
26. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Pianko MJ; Moskowitz AJ; Lesokhin AM Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972 [TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in the management of malignancies in transplant recipients. Regalla DKR; Williams GR; Paluri RK Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139 [TBL] [Abstract][Full Text] [Related]
30. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Shi LZ; Goswami S; Fu T; Guan B; Chen J; Xiong L; Zhang J; Ng Tang D; Zhang X; Vence L; Blando J; Allison JP; Collazo R; Gao J; Sharma P Cancer Immunol Res; 2019 Nov; 7(11):1803-1812. PubMed ID: 31466995 [TBL] [Abstract][Full Text] [Related]
31. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277 [TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416 [TBL] [Abstract][Full Text] [Related]
33. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Dong M; Meng Z; Kuerban K; Qi F; Liu J; Wei Y; Wang Q; Jiang S; Feng M; Ye L Cell Death Dis; 2018 Oct; 9(10):1039. PubMed ID: 30305604 [TBL] [Abstract][Full Text] [Related]
34. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. Gong Y; Chen M; Tan Y; Shen J; Jin Q; Deng W; Sun J; Wang C; Liu Z; Chen Q ACS Appl Mater Interfaces; 2020 Nov; 12(45):50248-50259. PubMed ID: 33135879 [TBL] [Abstract][Full Text] [Related]
35. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
36. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Wang C; Ye Y; Hochu GM; Sadeghifar H; Gu Z Nano Lett; 2016 Apr; 16(4):2334-40. PubMed ID: 26999507 [TBL] [Abstract][Full Text] [Related]
38. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991 [TBL] [Abstract][Full Text] [Related]
39. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903 [TBL] [Abstract][Full Text] [Related]
40. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]